Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…
Search results for: gout flare
Biosimilar for Infliximab Launched in Europe
Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information
Hospitalists Gain Insight on Signs, Symptoms of Infection Among Inpatients on Biologic Drugs
Rheumatologist at Society of Hospital Medicine conference provides treatment recommendations for hospital patients with rheumatic disease
Clinical Applications of Dual-Energy Computed Tomography for Rheumatology
Advanced imaging technique allows physicians to detect deposition of monosodium urate crystals not apparent in physical exams and better diagnose gout
Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered
Rheumatology Drug Updates: Apremilast, Golimumab, and More
Information on new approvals and medication safety rheumatologists need to know
The State-of-the-Art of Rheumatology Symposium
Experts from across the nation describe the best clinical approaches to rheumatologic disease management.
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety
Plan Now for ICD-10 Changeover
Coding changes will have an impact on staff, physicians, and even the finances of rheumatology practices
Drug Updates
Information on New Approvals and Medication Safety
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 17
- Next Page »